The ALPCO Calprotectin assay is a widely used diagnostic tool designed to measure calprotectin levels in human stool as a biomarker of intestinal inflammation. Calprotectin, a protein released by activated neutrophils, serves as a reliable indicator of inflammatory activity within the gastrointestinal tract. Elevated levels are commonly associated with conditions such as inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, making it a valuable non-invasive alternative to more invasive diagnostic procedures.

This clinical trial focuses on evaluating the accuracy, sensitivity, and clinical utility of the ALPCO Calprotectin assay in detecting and monitoring gastrointestinal inflammation. By analyzing stool samples from diverse patient populations, the study aims to assess how effectively calprotectin levels correlate with disease presence, severity, and progression. The assay’s ability to distinguish between inflammatory and non-inflammatory gastrointestinal disorders is of particular importance, as it may help reduce the need for unnecessary endoscopic procedures.

In addition to diagnostic applications, the study explores the role of calprotectin as a tool for ongoing disease management. Monitoring changes in calprotectin levels over time can provide insight into treatment response and potential relapse, allowing clinicians to make more informed decisions regarding patient care. This approach supports a more personalized and proactive model of treatment, improving outcomes while minimizing patient burden.

Overall, the ALPCO Calprotectin clinical trial contributes to the growing body of evidence supporting non-invasive biomarkers in gastrointestinal medicine. By validating the reliability and clinical relevance of stool-based calprotectin testing, the study reinforces its role as an essential component in modern diagnostic and monitoring strategies for inflammatory bowel diseases and related conditions.